XLV250103C154000
- 0.00
- 0.000.00%
The Health Care Select Sector SPDR® Fund Newsroom
Arbutus Could Benefit From Big Pharma Bird Flu Vaccines: Jefferies
Anteris Technologies Positioned To Capture 4%-5% Of US Transcatheter Valve Replacement Market By 2030: Analyst
These Stocks Are Expected to See at Least 25% Revenue Growth in 2025 – Wolfe
Bullish Outlook On Instil Bio's Investigational Cancer Drug: Jefferies Sees Over 300% Stock Upside
Unpacking the Latest Options Trading Trends in Merck & Co
FDA Issues Draft Guidance on Developing Weight Loss Drugs
Citi Says 'Buy' These Stocks in '25; SA Quant Ratings Says Maybe Not
Moderna, Novavax and Other Vaccine Names Extend Gains Amid COVID/flu Concerns
Market Sells CES Tech News, ISM Tuesday as Nvidia Champions Robots Monday | Live Stock
Eli Lilly's Options: A Look at What the Big Money Is Thinking
Sector Update: Health Care Stocks Mixed Premarket Tuesday
Johnson & Johnson Announces RYBREVANT Plus LAZCLUZE Show Statistically Significant And Clinically Meaningful Improvement In Overall Survival Versus Osimertinib; Median Overall Survival Improvement Expected To Exceed One Year; First And Only Regimen...
Bird Flu Claims First U.S. Life in Louisiana
Market Climbed Monday Just Past Santa Rally High Water Mark | Wall Street Today
Danaher Analyst Ratings
AbbVie Announced Q4 2024 Earnings To Include $1.6B Acquired IPR&D Costs, Impacting EPS By $0.88; Final Results Pending; Q4 Adj EPS $2.06-$2.10; FY24 Adj EPS Guidance $10.02-$10.06
Sentiment Has Been Shifting Away From Small Caps and Cyclicals
Wells Fargo Spotlights 31 Names It Believes 'Offer Above-average Growth Potential'
FDA Issues First Draft Guidance on Use of AI in Drug, Medical Device Development
Stock Of The Day: Will Johnson & Johnson Take The Market Lower?